The Philadelphia Fed saw its primary gauge measuring the sector jump from 0.3 in June to 21.8, far better than Wall Street estimates of 5 and the highest in a year.Economyread more
Stocks fell for a third straight day on Thursday as Wall Street digested a mixed batch of corporate earnings results.US Marketsread more
It's tempting to view Netflix as a possible replacement for the entire media ecosystem. But execs on its Q2 earnings call showed lower ambitions: It just wants to create the...Technologyread more
Hacker Square at Facebook's headquarters pays homage to the company's early motto of moving fast and breaking things.Technologyread more
Video of the event does not show the president disagreeing with his supporters. Instead, it shows that Trump paused as the chant began, allowing his supporters to continue...Politicsread more
These are the stocks posting the largest moves midday.Market Insiderread more
Jeffrey Epstein, a former friend of Presidents Donald Trump and Bill Clinton, had asked a judge to release him on a bond of as high as $100 million or more.Politicsread more
Netflix blames its content slate, regional price increases and a "pull-forward effect" of its strong Q1 growth for the miss.Technologyread more
Jim Bridenstine, the leader of NASA, told CNBC his predictions for the future of the space industry.Investing in Spaceread more
Nancy Pelosi and House Democrats contend the $15 per hour minimum wage bill will lift workers who have not seen the benefits of a strong economy.Politicsread more
The strengthening of the president's formidable campaign war chest has led his organization, along with the Republican National Committee, to raise over $100 million in the...2020 Electionsread more
The Food and Drug Administration said Tuesday it has sent a warning letter to drug distributor McKessson for allegedly shipping "illegitimate" opioid products and failing to properly handle and investigate the incidents.
Specifically, the FDA is accusing McKesson of failing to identify, quarantine and investigate drug shipments that had been tampered with. Some of the bad shipments were discovered at three Rite Aid pharmacies in Michigan. This is the first time the FDA has issued a warning letter under the 2013 Drug Supply Chain Security Act.
Distributors have come under fire for their role in the opioid crisis. McKesson and Cardinal Health are the subject of numerous lawsuits alleging they flooded communities with opioids.
"A distributor's failure to have systems in place to investigate and quarantine suspect and illegitimate products within their control is a violation of the law. But this is even more concerning given that we're in the midst of a widespread opioid crisis," FDA Commissioner Scott Gottlieb said in a statement.
The warning letter was dated Feb. 7.
McKesson in a statement said it takes this situation "very seriously."
"We have been in communication with the FDA over the past several months to respond to their questions and we are in the process of providing additional procedural detail and documentation, including enhancements recently made in response to the FDA's initial feedback," the company said in a statement Tuesday. "We are committed to the security of the supply chain and are taking steps to help ensure we comply fully with FDA's track-and-trace laws for all pharmaceutical products."
In its warning letter, the FDA cited three examples where McKesson shipped prescription drugs that were supposed to be opioids and pharmacies discovered the opioid pills were removed and replaced with other products.
"This is simply unacceptable," Gottlieb said.
In September and October 2016, three Rite Aid pharmacies in Michigan reported receiving bottles oxycodone hydrochloride that were instead filled with naproxen and in one case, a combination of naproxen and ciprofloxacin hydrochloride, the FDA said.
Though McKesson investigated the incidents, the FDA said the company did not demonstrate that it identified all illegitimate products and notified its other customers who might have received products from the same batch.
In December 2016, Albertsons pharmacy submitted illegitimate product notifications for divalproex and losartan potassium and hydrochlorothiazide it received from McKesson because the packages allegedly did not contain lot numbers or expiration dates, the agency said.
The FDA also said in June 2016, drugmaker GlaxoSmithKline notified McKesson that a pharmacy reported receiving two sealed bottles of a product labeled as Triumeq that actually contained gemfibrozil. In this case, McKesson was unable to provide records showing it identified illegitimate product or other requirements, the FDA said.
Warning letters serve as the first step in any regulatory action the FDA may take against a company. The FDA floated taking possible legal action, including seeking an injunction.
McKesson has 15 days from the time it receives the letter to outline the steps it has taken to correct the violations flagged by the FDA and to identify and conduct investigations related to other reports of suspicious or illegitimate shipments.
Correction: This story was revised to correct that it's the first time the FDA has issued a warning letter under the 2013 Drug Supply Chain Security Act.